CLINICAL_TRIALS ClinicalTrials.gov record update

Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06859008
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:08.103337+00:00
Published At: 2026-04-20T00:00:00+00:00
Record Updated At: 2026-04-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Splenic Marginal Zone Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-20"
protocolSection.identificationModule.nctId: "NCT06859008"
protocolSection.identificationModule.officialTitle: "Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.